Axa S.A. Sells 66,387 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)

Axa S.A. trimmed its position in NewAmsterdam Pharma (NASDAQ:NAMS) by 19.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 278,266 shares of the company’s stock after selling 66,387 shares during the quarter. Axa S.A. owned about 0.30% of NewAmsterdam Pharma worth $7,151,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the company. JPMorgan Chase & Co. grew its stake in shares of NewAmsterdam Pharma by 176.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 22,351 shares of the company’s stock worth $371,000 after buying an additional 14,280 shares in the last quarter. Legal & General Group Plc grew its position in NewAmsterdam Pharma by 24.8% in the fourth quarter. Legal & General Group Plc now owns 22,946 shares of the company’s stock worth $590,000 after acquiring an additional 4,556 shares in the last quarter. American Century Companies Inc. purchased a new stake in NewAmsterdam Pharma during the fourth quarter valued at approximately $8,907,000. Geode Capital Management LLC lifted its stake in shares of NewAmsterdam Pharma by 1.6% in the 3rd quarter. Geode Capital Management LLC now owns 86,322 shares of the company’s stock valued at $1,433,000 after purchasing an additional 1,399 shares during the last quarter. Finally, Swiss National Bank lifted its stake in shares of NewAmsterdam Pharma by 105.1% in the 4th quarter. Swiss National Bank now owns 72,000 shares of the company’s stock valued at $1,850,000 after purchasing an additional 36,900 shares during the last quarter. 89.89% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at NewAmsterdam Pharma

In other news, Director James N. Topper acquired 1,135 shares of the business’s stock in a transaction dated Wednesday, March 26th. The shares were purchased at an average price of $22.49 per share, with a total value of $25,526.15. Following the transaction, the director now directly owns 3,013,569 shares in the company, valued at approximately $67,775,166.81. This represents a 0.04 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Louise Frederika Kooij sold 150,000 shares of the stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $20.37, for a total transaction of $3,055,500.00. Following the sale, the chief accounting officer now directly owns 15,000 shares of the company’s stock, valued at $305,550. The trade was a 90.91 % decrease in their position. The disclosure for this sale can be found here. 19.50% of the stock is currently owned by corporate insiders.

NewAmsterdam Pharma Price Performance

Shares of NAMS opened at $19.00 on Wednesday. The firm has a market capitalization of $2.09 billion, a price-to-earnings ratio of -7.31 and a beta of 0.01. The company has a 50-day moving average of $19.65 and a 200 day moving average of $21.24. NewAmsterdam Pharma has a 1-year low of $14.06 and a 1-year high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.47). The company had revenue of $12.77 million during the quarter, compared to analysts’ expectations of $3.30 million. On average, equities analysts anticipate that NewAmsterdam Pharma will post -1.75 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on NAMS shares. HC Wainwright restated a “buy” rating and set a $48.00 price target on shares of NewAmsterdam Pharma in a report on Tuesday, January 14th. Royal Bank of Canada restated an “outperform” rating and issued a $40.00 target price on shares of NewAmsterdam Pharma in a report on Friday, January 24th. Scotiabank upped their price target on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a “sector outperform” rating in a report on Thursday, February 27th. UBS Group set a $41.00 target price on NewAmsterdam Pharma in a research report on Monday, March 3rd. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $42.00 price target on shares of NewAmsterdam Pharma in a report on Tuesday, April 8th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $43.33.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.